Video Library

Search the Video Library

Filter by Date

Video Language

Filter by Cancer Type:

Displaying Results 16 - 30 of 48

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Lung Cancer Video Library

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

¿Cómo los subtipos histológicos del cáncer pulmonar de células no pequeñas alteran las recomendaciones en el estadio avanzado?

For our third video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss how NSCLC subtype (histology) can alter chemotherapy recommendations in advanced

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses the changing standard of care for stage 3 non-small cell lung cancer (NSCLC).

Lung Cancer Video Library Spanish - Raez IMMUNOTERAPIA PARA CANCER DE PULMON DE CELULAS NO PEQUENAS

We are pleased to offer additions to our Lung Cancer Video Library for our Spanish speaking community. Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr. Luis Raez nos brinda información actualizada. En este video, el Dr. Raez

Lung Cancer Video Library Spanish - Domingo - NECESIDAD DE DIAGNOSTICO MOLECULAR EN CANCER DE PULMON (NGS Y pd-l1 TESTS)

We are pleased to offer additions to our Lung Cancer Video Library for our Spanish speaking community. Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información

Lung Cancer Video Library Spanish - Domingo - BIOPSIAS LIQUIDAS Y CANCER DE PULMON

We are pleased to offer additions to our Lung Cancer Video Library for our Spanish speaking community. Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información

普通话肺癌视频库-免疫治疗在不可切除的3期NSCLC中的作用

Dr. Jenny Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the role of immunotherapy for unresectable stage 3 non small cell lung cancer. Check back for more in

普通话肺癌视频库-NSCLC 3期放化疗后的巩固免疫治疗

Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on which stage 3 non small cell lung cancer patients should receive consolidation immunotherapy after

普通话肺癌视频库-晚期NSCLC和高PDL-1的领先治疗方案

Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the leading treatment options for patients with advanced NSCLC and high tumor PD-L1 expression. To join